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Abstract 
Friedreich’s ataxia is an inherited neurodegenerative disease caused by frataxin deficiency. 
Frataxin is a conserved mitochondrial protein that plays a role in Fe-S cluster assembly in 
mitochondria. Fe-S clusters are modular cofactors that perform essential functions 
throughout the cell. They are synthesized by a multi-step and multi-subunit mitochondrial 
machinery that includes a scaffold protein Isu for assembling a protein bound Fe-S cluster 
intermediate. Frataxin interacts with Isu, iron, and with the cysteine desulfurase Nfs1 that 
supplies sulfur, thus placing it at the center of mitochondrial Fe-S cluster biosynthesis. 
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Introduction 
Friedreich’s ataxia is an inherited disease characterized by progressive symptoms of ataxia and 
sensory loss, often leading to gait impairment and the need for a wheelchair. A progressive and 
sometimes lethal cardiomyopathy is another feature and in some cases diabetes mellitis is 
associated. At the pathological level, degenerative changes affect certain large sensory neurons, 
heart cells and islet cells, thus involving a unique target tissue distribution (1). The gene was 
identified by genome mapping of affected kindreds, and the encoded protein, frataxin, is decreased 
in affected individuals most often due to a GAA repeat in the first intron of the gene (2). The protein 
is found primarily in mitochondria (3). Human frataxin is synthesized on cytoplasmic ribosomes 
with a mitochondrial targeting sequence that mediates organelle targeting and is subsequently 
removed by proteolytic processing steps in the mitochondrial matrix (4-7). Deficiencies of aconitase 
and other mitochondrial iron-sulfur (Fe-S) proteins occur as first noted in cardiac biopsies of 
affected individuals (8). Fe-S clusters are modular cofactors consisting of iron and sulfur, most often 
anchored by bonds joining cysteine sulfur atoms in the polypeptide chain of a protein and iron atoms 
of the cluster. They perform essential and diverse biochemical functions (electron transfer in cellular 
respiration, substrate interaction, biological signal transduction among other functions), and their 
biogenesis is catalyzed by a multisubunit machinery (9). Frataxin has been a subject of intense 
study with contributions from many disciplines: structural biology, cell biology, genetics of model 
organisms, evolutionary biology, and medicine. A picture is emerging of a direct role of frataxin in 
the complex and highly conserved machinery of Fe-S cluster biogenesis in mitochondria. Additional 
functions may be mediated by direct frataxin-iron effects or by other protein-protein interactions.   
 
Frataxin Evolution 
 Frataxin is highly conserved throughout evolution, being present in humans, plants, flies, worms, 
and bacteria (proteobacteria but not archaebacteria) (10). Some hints about frataxin function can be 
gleaned from the evolutionary record. Three different bacterial operons have been identified capable 
of mediating Fe-S clusters assembly: nif, suf and isc. The nif operon is specialized for high volume 
biosynthesis needed to support nitrogenase synthesis during diazotropic growth of some organisms 
(e.g. Azotobacter vinlandii). The suf operon is specially adapted for Fe-S cluster synthesis in 
conditions of iron starvation and oxidative stress. Finally the isc operon handles housekeeping Fe-S 
cluster biogenesis (9). Although not found on any of these operons, frataxin is strongly associated 
with the isc operon. It appeared in proteobacteria about the time that the specialized chaperones 
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hscA and hscB appeared on the isc operon. A frataxin homolog was subsequently lost in this 
phylogenetic lineage on two separate occasions, coinciding with loss of hscA and hscB. Frataxin’s 
appearance in eukaryotes occurred about the time of the endosymbiotic event creating mitochondria 
from the purple bacterial ancestor, and it was probably acquired by mitochondria together with 
other components of the isc operon (10). This notion of co-evolution of frataxin and Fe-S assembly 
components of the isc operon is supported by studies of primitive eukaryotes that lack typical 
mitochondria. In Trichomonas vaginalis, a unicellar parasite, a modified and stripped-down 
organelle called the hydrogenosome performs Fe-S cluster assembly and contains a frataxin 
homolog able to complement the phenotypic defects of a yeast mutant lacking its own frataxin (11). 
An even more severe case of organelle simplification is presented by mitosomes. These are 
rudimentary organelles of obligate intracellular parasites called microsporidia, and they lack 
respiratory complexes or mitochondrial DNA. Virtually all that remains are a few components 
recognizable for their homology to Fe-S cluster assembly components (e.g. Isu, Nfs1, Hsp70 
homologs) and frataxin (12). The co-retention of frataxin with these very few other components 
involved in Fe-S cluster assembly in the mitosome emphasizes their close functional relationship.  
 
Mitochondrial iron accumulation  
In Saccharomyces cerevisiae, Yfh1 is the yeast frataxin homolog, and the initial studies of the 
∆yfh1 deletion strain described a pleiomorphic phenotype. The mutant exhibited constitutive 
upregulation of the cellular iron uptake system and tremendous accumulation of iron in 
mitochondria (13). The accumulated iron appeared as dense aggregates in unstained electron 
micrographs. Chemical analyses revealed the accumulated iron was in the form of ferric phosphate 
micelles (14). Many additional studies have established a close association of the mitochondrial iron 
accumulation phenotype and deficiency of Fe-S clusters. Cellular depletion studies in which Yfh1 
was put under control of a regulated promoter and turned off recapitulated the phenotypes of 
deficient Fe-S cluster proteins and mitochondrial iron accumulation. If the promoter was turned on 
again, Fe-S clusters were restored and the accumulated iron returned to a normal distribution (15). 
Other mutants of the mitochondrial Fe-S cluster assembly pathway were similarly associated with 
this iron homeostatic phenotype (ssq1, jac1, nfs1, others). In human cells, mitochondrial iron 
accumulation has also been observed, both in tissues from Friedreich’s patients (e.g. heart, dorsal 
root ganglia) and in cultured cells engineered to exhibit stable frataxin deficiency (16). Thus low 
level frataxin is associated with mitochondrial iron accumulation and Fe-S cluster deficiency in both 
human and yeast cells, indicating a remarkable degree of conservation of the iron homeostatic 
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machineries (17). The presumption is that there exists a conserved regulatory Fe-S cluster protein 
or proteins mediating these effects. At this time however, although an unusual Fe-S cluster 
(liganded by glutathione and glutaredoxins) has been found to mediate control of cellular iron 
uptake in yeast (18,19), the controlling protein(s) for mitochondrial iron uptake or accumulation has 
not been identified for any species, and so the latter piece is still missing from our understanding.  
 
Fe-S cluster assembly in mitochondria: Frataxin has been found in mitochondria of virtually all 
eukaryotes using biochemical and microscopic tools to ascertain its subcellular location. Similarly, 
homologs of the other Isc Fe-S cluster assembly components have been found in mitochondria (20). 
The steps and components involved in the biogenesis of Fe-S cluster proteins in mitochondria are 
quite similar to those in bacteria. The process can be understood in terms of the central role of 
scaffolds as first shown by Dennis Dean and now well established (21). An Fe-S cluster intermediate 
is first formed on the scaffold protein Isu and then transferred to apoproteins (Fig. 1). Many steps 
must occur in a coordinated fashion for proper Fe-S cluster synthesis on Isu. The sulfur for Fe-S 
clusters originates from cysteine via the action of Nfs1, a pyridoxal phosphate containing cysteine 
desulfurase. In eukaryotes, Nfs1 must be assembled with Isd11, a small accessory subunit of 
unknown function (22,23). The sulfur is probably transferred to Isu from the Nfs1 active site as a 
persulfide. The source of the iron for the Isu intermediate is unclear, although a role for 
mitochondrial carrier proteins Mrs3 and Mrs4 in yeast (mitoferrin in humans) has been proposed 
(24). Frataxin may play a role here and has been shown to genetically interact with the 
mitochondrial carrier proteins. This is shown by the exacerbated slow growth and mitochondrial 
iron starvation in the combined ∆mrs3∆mrs4∆yfh1 mutant (25). Other components implicated at 
this stage are Arh1 and Yah1 (adrenodoxin reductase and adrenodoxin in humans), which are 
needed to provide reducing equivalents in an electron transfer chain, although the substrate 
requiring reduction has not been defined (26). The Isu protein appears to be conserved in the 
context of primary sequence and function, and structural information exists for a few bacterial 
homologs. Key features are three critical cysteines and an aspartate that bind the cluster 
intermediate probably on each subunit of the Isu dimer (27). 
 
Following formation of the Isu scaffold intermediate, several additional components are required 
for transfer of the intermediate to recipient apoproteins. The scaffold Isu displays an interaction site 
consisting of the tripeptide sequence, PVK, and this mediates binding to the Hsp70 chaperone (Ssq1 
in yeast and Ssc1 in humans) (28,29). This interaction is modulated by the ATP hydrolysis cycle in 
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conjunction with accessory proteins Jac1 and Mge1 
here (31). The proteins destined to become Fe
cytoplasmic ribosomes as precursor proteins with mitochondrial targeting sequences. Upon import 
into mitochondria, the unfolded precursors are subjected to various processing steps that remove the 
targeting sequences (32), and the mature apoproteins thus generated become substrates for transfer 
of Fe-S clusters from Isu (Fig. 1).  
Fig. 1: Scheme showing role of yeast frataxin (Yfh1) in mitochondrial Fe
mitochondrion is shown as an oval bounded by a double membrane. Yfh1 is shown as a helix
(green and tan). A. Mitochondrial carriers Mrs3 and Mrs4 (box) play a role in transfer of iron in some form 
(Fe-X) across the mitochondrial inner me
the enzyme Nfs1 and its accessory protein Isd11 to provide sulfur for Fe
equivalents are provided by the reductase Arh1 in the membrane and the associated fe
physically interacts with Nfs1, Isd11, and Isu. B. The Fe
the scaffold Isu, which interacts with Nfs1, Isd11 and Yfh1. Another complex is formed by Isu and Ssq1, Jac1, 
Mge1 with the binding site being provided by the PVK tripeptide on Isu1. Grx5 acts at this step. C. The 
precursor proteins (squiggly black lines) are nuclear encoded, translated on cytoplasmic ribosomes, and 
targeted to mitochondria and imported in unfolded state. After 
acquire the Fe-S cluster cofactor (red diamond) by action of the chaperones and glutaredoxin.
|  Timothy Stemmler, et. al 
 
(30). A monothiol glutaredoxin is also implicated 
-S cluster proteins in mitochondria are
-S cluster assembly. 
mbrane. Cysteine (Cys-SH) enters mitochondria and is acted on by 
-S clusters. Electrons or reducing 
-S cluster intermediate (red diamond) is assembled on 
proteolytic processing they are folded and 
 translated on 
 
The 
-sheet sandwich 
rredoxin Yah1. Yfh1 
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Epistasis and placement of  Yfh1 within the pathway of  Fe-S cluster assembly 
 The central component in Fe-S cluster assembly in mitochondria is the Isu scaffold. In order to 
begin to address the function of frataxin, it was important to determine if frataxin acts before Isu, in 
formation of the Fe-S cluster intermediates, or after Isu, in the transfer of the Isu intermediates to 
apoproteins. In one approach to this problem, a form of metabolic labeling was devised in which 
radioactive iron was added to growing yeast cells, and the radiolabeled Fe-S cluster Isu 
intermediate was recovered by immunoprecipitation (33). This approach was combined with 
promoter swaps to produce cellular depletion of one or another of the assembly component(s) prior 
to iron labeling and Isu recovery. A reduction in iron labeling of Isu would indicate decreased 
formation of Fe-S cluster intermediates. In that case, the depleted component was placed upstream 
of Isu, because it was necessary for intermediate formation. In the case of increased iron labeling of 
Isu, the component placed downstream of Isu, because it was needed for transfer of the Isu clusters 
to recipient apoproteins. Using this assay design, Nfs1, Arh1, Yah1 were placed upstream, and Ssq1, 
Jac1, and Grx5 were placed downstream of Isu in the Fe-S cluster assembly process. Frataxin was 
placed upstream, because frataxin depleted cells failed to efficiently form the radiolabeled Isu 
intermediate (34). 
 
A completely independent set of observations led to a similar conclusion. The manganese 
superoxide dismutase (MnSod), the dismutase of the mitochondrial matrix, was found to incorporate 
iron instead of manganese in some settings, with concomitant inactivation of the enzyme. For 
example, some of the Fe-S cluster assembly mutants with a mitochondrial iron accumulation 
phenotype were associated with MnSod mismetallation. Specifically, these mutants, such as ssq1 
and grx5, belonged to Isu downstream events in transfer of Fe-S cluster intermediates to 
apoproteins (35). By contrast, although frataxin mutants (∆yfh1) dramatically accumulated iron in 
mitochondria, the iron was not available for (mis)incorporation into MnSod (36). Similarly Isu 
mutants (depletion or dominant negatives) were also not associated with MnSod inactivation (35). 
These data suggest frataxin should be grouped with Isu in the upstream part of the Fe-S cluster 
biogenesis pathway and distinguished from Ssq1 and Grx5.  Although mismetallation is an aberrant 
situation, these observations may point to a physiological role of frataxin in modulating bioavailable 
iron pools in mitochondria.  
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Effects of  frataxin in promoting Fe-S cluster assembly in mitochondria 
 Two experiments are presented to illustrate the role of frataxin in promoting Fe-S cluster 
assembly in mitochondria. In the first experiment, mitochondria were isolated from wild-type or 
∆yfh1 strains. New synthesis of Fe-S clusters in the isolated organelles was examined by providing 
35S-cysteine as a source of sulfur. In the wild-type, radioactive sulfur was incorporated into a pool of 
apoaconitase by the mitochondrial Fe-S cluster machinery. Synthesis of new clusters was also 
detected by labeling of imported ferredoxin, and these could be distinguished by signals on a native 
gel (Fig. 2A, left panel; Fig. 2B, lanes 1 and 2). In the mutant, however, no such labeling occurred, 
indicating failure to make Fe-S clusters (Fig. 2A, middle panel; Fig. 2B, lanes 5 and 6). 
Subsequently, frataxin was imported into the ∆yfh1 mutant mitochondria and the mitochondria 
were recovered by centrifugation. When a similar 35S-cysteine labeling experiment was performed, 
the mutant mitochondria demonstrated restored ability to make Fe-S clusters on both aconitase and 
imported ferredoxin (Fig. 2A, right panel; Fig. 2B, lanes 7 and 8). Thus a very small amount of 
frataxin (estimated less than one picomole) imported into isolated ∆yfh1 mitochondria even without 
iron addition was able to rapidly (in less than 10 minutes) restore Fe-S cluster synthesizing activity. 
This effect in isolated mitochondria shows that everything is present in mitochondria for Fe-S 
cluster formation and that a small quantity of frataxin activates or mediates the process (25). 
 
In the second experiment, a more reductionist approach was taken with purified proteins. Isu was 
expressed and purified from bacteria in the apoprotein form, without any cluster. If Isu was 
incubated with elemental iron and sulfur, a small amount of Fe-S cluster intermediate could be 
detected as shown by appearance of the characteristic absorption spectrum (Fig. 3, tracing B). In a 
parallel incubation, Isu was added to elemental sulfur and iron loaded frataxin monomer instead of 
elemental iron alone. The absorbance tracing (Fig. 3, tracing A) followed over time showed 
tremendous facilitation in the presence of frataxin. In this experiment, Drosophila frataxin was 
used because of its greater stability, and a D37A mutant of yeast Isu was used to trap and stabilize 
the intermediate on Isu (37). A similar assay showed activity of human frataxin in facilitating Fe-S 
cluster formation on the human Isu scaffold protein (38). These experiments with purified 
components demonstrate that frataxin possesses the ability to facilitate Fe-S cluster formation on 
Isu. 
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Fig. 2: Imported frataxin (Yfh1) restores Fe
mitochondria (left panel) synthesize Fe
Mutant ∆yfh1 (middle panel) fail to synthesize
mitochondria (right  panel) now synthesize clusters. B. Mitochondria were isolated from wild
strains. Full length yeast frataxin (produced and radiolabeled on methionine and cysteine in 
was imported (18 degrees, 10 min, lanes 3, 4, 7, 8) and mitochondria were recovered by centrifugation. In the 
second stage, 35S-cysteine and ferredoxin precursor Yah1 were imported 10 min, 30 degrees). The 
mitochondria were recovered and the matrix fraction analyzed by a native gel and autoradiography (lanes 1
8). The imported Yfh1 labeled on the polypeptide is visible on the gel. The imported ferredoxin labeled on the 
sulfur of the Fe-S is visible in ∆yfh1
endogenous aconitase labeled on its Fe
|  Timothy Stemmler, et. al 
 
-S cluster assembly in isolated yeast mitochondria. A. Wild
-S clusters on endogenous Apoaconitase and imported ApoYah1.  
 clusters. Following Yfh1 precursor import mutant 
 mitochondria only following Yfh1 import (lanes 5, 6). Similarly, 
-S cluster is visible in ∆yfh1 only following Yfh1 import (lanes 5, 6) 
 
 
-type 
∆yfh1 
-type or ∆yfh1 
the polypeptide) 
-
(25).  
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Fig. 3: Frataxin facilitates the rate and efficiency of Fe
expressed and purified from bacteria in the apoprotein form (D37A mutated form of Isu1). Mature drosophila 
frataxin Dfh was likewise expressed and purified from bacteria. The reactions contained 100 µM Isu scaffold. 
To this was added sulfur (2.4 mM Na
frataxin (100 µM of Dfh-iron monomer) (tracing A). The formation of cluster on Isu was followed by absorbance 
at 426 nm. Time dependence data from tracing A was fit with a rate equation for a first order process (panel
Frataxin structures 
 Structures have been obtained for yeast 
strikingly alike, characterized by an alpha
α-helical plane consists of two parallel (N and C terminal) alpha helices, and the 
consists of five anti-parallel beta sheets; a sixth and possibly seventh strand intersect the planes 
depending on the species (42). The structure and length of the respective N
orthologs, while the unstructured C
(43). A negatively charged surface is created by clustering of contiguous acidic residues c
by portions of helix 1 and beta sheet 1. Although the individual residues are not always conserved, 
all known frataxins are characterized by the presence of such an acidic surface. A second conserved 
structural feature is a neutral flat area on 
|  Timothy Stemmler, et. al 
 
-S cluster formation on Isu scaffold. Yeast Isu was 
2S) and iron (100 µM ferrous ammonium sulfate) (tracing B) or iron
(37).  
(39), human (40) and bacterial (41)
-beta sandwich motif creating the two protein planes. The 
-termini vary among 
-termini, also of variable length, help control protein stability
the beta sheet surface, with more hydrophobic towards 
 
-
 C) 
 frataxins. They are 
β-sheet plane 
 
ontributed 
Frataxin and mitochondrial Fe-S cluster biogenesis |  Timothy Stemmler, et. al 
DIGITALCOMMONS@WSU  |  2010 11
the center and more hydrophilic towards the periphery. This region contains a number of perfectly 
conserved residues that appears to be well suited to mediate interaction with a protein partner. 
 
Isu interaction 
 A functional relationship of frataxin and Isu was initially suggested by genetic experiments 
showing synthetic lethality of ∆yfh1 (YFH1 gene deleted) and ∆isu1 (deletion of one of two 
homologous ISU genes causing lowered levels of Isu) (44). Physical interactions between frataxin 
and Isu were subsequently demonstrated in pull-down experiments from mitochondrial lysate. 
Interestingly the pull-down of Yfh1 by Isu, or reciprocally of Isu by Yfh1, was dependent on iron 
addition to the buffer (50 µM ferrous ammonium sulfate), and then inhibited by the presence of the 
metal chelator EDTA (45). The clearest demonstration of the importance of frataxin-Isu interaction 
in Fe-S cluster assembly was provided by careful analyses of mutant alleles of frataxin that failed to 
interact. A frataxin mutant (N122A/K123T/Q124A) was constructed by alteration of conserved 
surface exposed residues of the strand 3 in an area predicted to mediate protein interactions 
(46)(Table 1, column 1). These mutations did not interfere with protein expression or stability, and 
in vitro studies showed no effect on iron binding. However, interaction with Isu was severely 
impaired as assessed by pull-down from mitochondrial lysates onto immobilized Yfh1-His6. In these 
experiments, the affinity of frataxin binding to Isu was markedly decreased from about 1 µM for the 
wild-type to a number greater than 12 µM for the mutant. Experiments with purified Yfh1 and Isu1, 
as distinguished from lysate containing these and other proteins, also showed the interaction and 
the reduced affinity of the mutant, confirming that the mutational effect was direct. Importantly, in 
vivo experiments performed with the same yfh1 mutant demonstrated reduced Fe-S cluster protein 
activities and increased iron accumulation in mitochondria. The N122K mutant similarly was 
associated with decreased Isu interaction and decreased Fe-S cluster enzyme activities. The N122K 
mutation corresponds to N146K in the human ortholog and has been associated with Friedreich’s 
ataxia. The wild-type and mutant proteins placed under control of a regulated promoter and 
expressed over a wide range of concentrations confirmed mutant phenotypes occurred over a wide 
range of expression levels (46). Other mutations were constructed that altered amino acids in 
exposed areas of the beta sheet (Q129A in strand 4, W131A in strand 4 and R141A in strand 5). 
These mutations were examined in vitro and in vivo, and they too showed decreased frataxin-Isu 
interaction and deficiency of Fe-S cluster proteins (47) (Table 1, column 2, Fig. 4). The studies with 
mutant alleles were especially informative because they avoided many of the secondary phenotypes 
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associated with the yfh1 deletion. The conclusion from these studies is the interaction between 
frataxin and Isu is required for Fe-S cluster assembly in the mitochondria. 
 
Table 1: Amino acids with effects on Yfh1-Isu 
interaction and Fe-S cluster proteins 
structure amino acid no. Ref 1 Ref 2 Ref 3 
beta 1 D101   x 
beta 1 E103   x 
beta 3 N122 x   
beta 3 K123 x   
beta 3 Q124 x   
beta 4 Q129  #1  
beta 4 W131  #2  
beta 5 R141  #3  
 
Ref 1 (46): Triple Yfh1 mutant N122A/K123T/Q124A, diminished Isu interaction, low aconitase and 
succinate dehydrogenase, iron accumulation 
Ref 2 (47): Single mutants #1 Q129A #2 W131A #3 R141A, diminished Isu interaction, low aconitase 
Ref 3 (55): Double mutant D101A/E103A, no interaction with Isu, aconitase decreased 
 
Iron binding 
Frataxins interact with iron in vitro, although not in the manner of typical iron binding proteins. 
Binding is relatively low affinity, occurs on the protein surface rather than in a cavity, and is 
mediated primarily by carboxylic amino acids rather than cysteines and histidines (48). Analysis of 
iron interaction with yeast frataxin monomer showed two ferrous atoms binding with affinity of 2.5 
to 5 µM as high spin iron. Chemical shifts and line broadening induced by exposure of 15N-labeled 
yeast frataxin to iron (ferrous iron under anaerobic conditions) further defined iron binding residues 
as primarily carboxylate-containing amino acids in the helix 1-strand 1 region (39,49). Studies with 
other frataxin orthologs gave similar results although with some variation in iron binding 
stoichiometry and affinity (human bound 6 atoms with Kd 12-55 µM (38), E. coli bound 2 atoms with 
Kd 4 µM (50), Drosophila bound 1 atom with Kd 6 µM (37)). Mutagenesis studies performed with the 
objective of correlating in vitro iron binding and in vivo function have been problematic in part 
because of the redundant nature of the iron binding site(s) distributed over a surface and mediated 
by multiple iron binding amino acids. In addition, various effects of iron binding to frataxin have 
been observed, some of which may be physiologically important and some of which may not be 
relevant.    
Frataxin and mitochondrial Fe-S cluster biogenesis 
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Some frataxins oligomerize when exposed to iron. Exposure of yeast or 
molar excess of elemental iron in the absence of competing cations induced oligomerization, but this 
did not occur with the human protein 
alanine completely abrogated iron dependent oligomerization of the yeast protein (Table 2, column 
1, Fig. 4). This triple mutant, when tested 
protein activities and iron homeostasis, even when expressed at low levels 
oligomerization is probably not required for Fe
both in vitro and in vivo assays within yeast. A D79A/D82A mutation abrogated ferroxidase activity. 
The D79A/D82A or E93A/D97A/E103A mutants showed decreased frataxin
vitro, and both of these mutant alleles were associated with increased oxidant sensitivity and 
decreased life span in vivo. However, these mutations had no effect on aconitase activity and no 
effect on mitochondrial iron accumulation 
important for Fe-S cluster biogenesis. 
|  Timothy Stemmler, et. al 
 
E. coli
(51). Mutation of three carboxylates D86, E90, and E93 to 
in vivo, showed no deleterious effects on Fe
-S cluster synthesis. Other mutations were tested in 
-
(53) (Table 2, column 2), and thus they are probably not 
 
 frataxins to 20-fold 
-S cluster 
(52). Thus frataxin 
iron interactions in 
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Fig 4: Frataxin ortholog sequence alignment and Yfh1 structure showing locations of mutations with effects 
on iron binding and/or Isu binding. A. Se
ClustalW with structural features on top. The colored amino acids have been studied by mutagenesis and are 
implicated in iron interaction (red), or Isu interaction (blue). B. Solution structure of
(PDB ID# 2GA5) with residues involved in Isu binding identified in blue.  C. Solution structure of monomeric 
apo-Yfh1 with residues involved in Fe binding identified in red 
 
By contrast, mutation of four acidic residues D86/E89/D101/E103 to alanine was more deleterious 
for Fe-S clusters: aconitase was decreased to 30% of wild
accumulation occurred. Iron binding to this mutant frataxin was not measured directly, although 
iron dependent Isu interaction in mitochondrial lysate was markedly decreased 
column 3). Another set of experiments illustrates the problem of redundancy in the acidic iron 
binding sites. A yeast frataxin mutant D86/E90/E93 gave no 
type), regardless of the frataxin expression level. The D101/E103 mutant displayed a modest 
phenotype with moderately lower aconitase. However, the combined mutant exhibited a severe 
phenotype with growth inhibition and 40% residual aconitase activity. Iron binding affinity of this 
combined mutant protein was reduced by tryptophan fluorescence titr
|  Timothy Stemmler, et. al 
 
quence alignment of yeast, human and E. coli
 monomeric apo
(39)
-type levels and 
in vivo phenotype (compared with wild
ation but was not abolished 
 
 frataxin using 
-Yfh1 
.  
mitochondrial iron 
(54) (Table 2, 
-
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(55) (Table 2, column 4). Interestingly, the frataxin-Isu iron dependent interaction tested with 
purified proteins was abrogated by the D101/E103 or the combined D886/E90/E93/D101/E103 
mutations (55). We determined mutational effects of amino acids that showed strong interactions 
with Fe2+ in an NMR study with 15N–labeled Yfh1. Two possible iron binding sites were identified, 
one site consisting of D68/E93/H95 (site 1) and the other consisting of D101/E103 (site 2). Mutation 
of site 1 residues to alanine had no discernable effect on in vivo phenotypes, mutations of site 2 had 
a very mild effect (aconitase 90%), although iron binding stoichiometry for these mutants was 
decreased such that only one iron bound per molecule. Combined mutations of site 1 and site 2 
showed no iron binding by ITC or NMR titrations, and the in vivo phenotypes were quite severe, 
with aconitase of 37%, slow growth, and mitochondrial iron accumulation. These data show a 
correlation of frataxin iron binding and Fe-S cluster assembly activity i.e. the mutated iron binding 
sites were correlated with severely compromised Fe-S cluster assembly activity (Table 2, column 5, 
manuscript in preparation).  
TABLE 2: Yfh1 iron binding amino acids and their effects on Fe-S cluster 
assembly.  
 
structure amino 
acid no. 
Ref 1 Ref 2 Ref 3 Ref 4 Ref 5 
alpha 1 D79  #1    
alpha 1 D82  #1    
alpha 1 D86 x  x #1 #1 
alpha 1 E89   x   
alpha 1 E90 x   #1  
alpha 1 E93 x #2  #1 #1 
alpha 1 H95     #1 
alpha 1–beta 1 D97  #2    
beta 1 D101   x #2 #2 
beta 1 E103  #2 x #2 #2 
Ref 1 (52): Triple Yfh1 mutant D86A/E90A/E93A , no oligomerization in response to iron exposure in vitro,  
normal Isu interaction, no Fe-S deficit, no iron accumulation 
Ref 2 (53): Double Yfh1 mutant #1 D79A/D82A, low ferroxidase, oxidant sensitivity, normal aconitase, no 
iron accumulation. Triple Yfh1 mutant #2 E93A/D97A/E103A, oxidant sensitivity, normal aconitase, no iron 
accumulation . 
Ref 3 (54): Quadruple mutant D86A/89A/E101A/E103A , decreased iron dependent Isu interaction, low 
aconitase, iron accumulation . 
Ref 4 (55): Triple Yfh1 mutant #1 D86/A/E90A/E93A,  decreased iron binding affinity, normal aconitase, no 
iron accumulation. Double mutant #2 D101A/E103, decreased iron binding affinity, mild low aconitase, no 
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growth defect. Combined mutant #1 and #2: D86A/E90A/E93A/D101A/E103A , decreased iron binding affinity, 
lower aconitase, slow growth.  
Ref 5 (unpublished): Triple Yfh1 mutant #1 D86A/E90A/E93A,  decreased iron binding stoichiometry, 
normal aconitase, no iron accumulation.  Double mutant #2 D101A/E103A, decreased iron binding 
stoichiometry, slight decrease aconitase, no growth defect. Combined mutant #1 and #2 
D86A/E90A/E93A/E101A/E103A, no iron binding in vitro, decreased aconitase, iron accumulation, slow 
growth. 
 
How frataxin might work 
 In summary, frataxin interacts with the Fe-S cluster assembly scaffold protein Isu using frataxin’s 
beta sheet surface. It also interacts with iron via surface carboxylates of the helix 1-strand 1 area. 
Furthermore the frataxin-Isu interaction is iron dependent. Various in vitro assays have 
demonstrated these interactions and in vivo experiments with mutant alleles have shown the 
importance of these interactions for Fe-S cluster formation. Frataxin might work as a metal 
chaperone similar to copper chaperones involved in copper trafficking and copper metallation of 
proteins. Copper chaperones function by high affinity interactions with copper and with recipient 
proteins. Copper is bound to the chaperone, then liganded between chaperone and target protein, 
and finally handed off to the target protein. The copper thus is never free in solution and is targeted 
to its correct destination in the cell by the protein-protein interactions between chaperone and 
target (56). Frataxin might work in a similar fashion by transiently binding iron in mitochondria, 
interacting with Isu in an iron dependent fashion, and finally transferring protein bound iron to Isu. 
However, the affinity of frataxin for iron is relatively low and coordination incomplete, with the 
carboxylate binding sites being completed by water molecules. The driving force and mechanism of 
metal transfer to recipients also might be different than for the copper chaperones. A prediction of 
this model is that the iron liganding sites should overlap or be contiguous with the Isu binding sites. 
This may be the case especially for the iron binding site on the strand 1 consisting of the conserved 
D101/E103 residues. Biochemical data suggest frataxin facilitates iron use for Fe-S cluster 
formation on Isu (38) (Fig. 3). Other functions in mitochondrial iron trafficking are also possible. In 
line with the iron chaperone idea, frataxin might bind iron and bind to other proteins, thereby 
targeting the metal for delivery to aconitase (57), ferrochelatase (14,39) and succinate 
dehydrogenase (58). Iron specific activities of frataxin have also been suggested, and some bypass of 
frataxin mutant phenotypes including Fe-S cluster deficiencies has been observed as a result of 
forced expression of mitochondrial ferritin (59).   
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Alternatively, the function of frataxin in Fe-S cluster biogenesis might be primarily a regulatory 
one. The iron dependent frataxin-Isu interaction might signal formation of a protein complex for 
creation of the Fe-S intermediate on Isu. Of note, pull down experiments from mitochondria with 
yeast frataxin as bait yielded not only Isu, but also Nfs1 (45) and Isd11 (46), the functional cysteine 
desulfurase complex responsible for providing sulfur for iron-sulfur. Perhaps the data are pointing 
to the existence of a multi-subunit complex consisting of frataxin, Isd11-Nfs1, and Isu. Such a 
complex would be well situated to mediate formation of the Isu bound Fe-S cluster intermediate. 
Iron and sulfur are toxic intermediates, and their insertion into Fe-S clusters must be controlled to 
avoid toxicity. Frataxin might regulate the flux of these key intermediates, permitting delivery of 
enough for physiologic Fe-S cluster formation and not so much as to create iron and/or sulfide 
toxicity. The source of iron and its biological form are not well understood. The sulfur generated by 
the action of Nfs1/Isd11 on cysteine may be provided to Isu as persulfide by direct protein 
interaction as observed for some bacterial components. A role for frataxin in regulating sulfur  
transfer has been proposed in bacteria (60,61). For eukaryotes, the interaction with Nfs1/Isd11 is 
not well defined and regulatory functions have not been defined for sulfur transfer. Structural 
details of the frataxin-Nfs1/Isd11 interaction also remain to be clarified. The details of the frataxin-
Isu interaction from the Isu side have not been solved, and these interactions might be competing in 
some manner with Isu-chaperone interactions that mediate transfer of the cluster intermediate to 
apoproteins.  
 
 
Is Friedreich’s ataxia a disease of  Fe-S cluster assembly? 
 If Friedreich’s ataxia is caused by frataxin deficiency and frataxin mediates Fe-S cluster assembly, 
the question arises whether the disease is caused by Fe-S cluster deficiency. As far as is known, 
neither the cellular phenotype nor the human disease phenotype can be explained by deficiency of a 
single Fe-S cluster protein. Perhaps it is the combined effects from decreased activities of many Fe-S 
cluster proteins that produces the peculiar tissue specific effects characteristic of the disease. Also 
the degree of frataxin deficiency may be important for producing the unique cellular disease 
phenotypes. Complete lack of frataxin is lethal for growing mammalian cells, and somewhere 
between 20-30% is needed for normal growth. In cells with these decreased levels of frataxin, some 
Fe-S cluster proteins are deficient and iron accumulates in mitochondria as in the human disease 
(16).  In humans, effects of frataxin deficiency are likely to be buffered to different degrees in 
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different tissues depending on redundancy with other proteins and tissue specific needs. The 
recently demonstrated role of mitochondrial ferritin and its ability to mitigate the effects of frataxin 
deficiency might be important in this regard (59), and thus red cell precursors which have the 
ability to express mitochondrial ferritin in some settings perhaps would not be as affected by 
frataxin deficiency as other tissues e.g. large bore sensory neurons. An inherited disease ascribed to 
Isu deficiency has been described, and this is characterized by some degree of Fe-S cluster deficiency 
and iron accumulation in affected tissues (62,63). Given the close functional association of frataxin 
and Isu, one might expect that the human deficiencies would phenocopy each other. However in 
Friedreich’s ataxia, a unique tissue distribution targets dorsal root ganglia, cerebellum, and heart 
muscle. In the Isu deficiency disease, by contrast, the features are skeletal muscle swelling and 
exercise intolerance; neurodegeneration is not a feature. Thus Isu deficiency and frataxin deficiency 
in humans bear some resemblance but the tissue specificities are distinct with the differences still 
unexplained. 
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